KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Acquisitions: 2014-2016

  • Travere Therapeutics' Acquisitions was N/A to $115,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $63.2 million, marking a year-over-year change of. This contributed to the annual value of $95.3 million for FY2020, which is N/A change from last year.
  • Latest data reveals that Travere Therapeutics reported Acquisitions of $115,000 as of Q4 2016, which was down 77.00% from $500,000 recorded in Q2 2016.
  • Travere Therapeutics' Acquisitions' 5-year high stood at $33.4 million during Q1 2015, with a 5-year trough of $115,000 in Q4 2016.
  • In the last 3 years, Travere Therapeutics' Acquisitions had a median value of $14.8 million in 2014 and averaged $15.8 million.
  • Data for Travere Therapeutics' Acquisitions shows a peak YoY rose of 14.68% (in 2015) over the last 5 years.
  • Quarterly analysis of 3 years shows Travere Therapeutics' Acquisitions stood at $29.1 million in 2014, then grew by 14.68% to $33.4 million in 2015, then reached $115,000 in 2016.
  • Its Acquisitions was $115,000 in Q4 2016, compared to $500,000 in Q2 2016 and $33.4 million in Q1 2015.